MedTrace Logo

A Study of Real-World Outcomes of People With Crohn's Disease (CD)

NCT05056441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 623

Last updated 2022-10-21

No results posted yet for this study

Summary

The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST).

In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to visit a study doctor during this study.

Conditions

  • Crohn Disease

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Australia
  • Belgium
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056441 on ClinicalTrials.gov